EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. (Q37767383)

22 August 2017

1 reference

title

EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. (English)

1 reference

non-small-cell lung carcinoma

22 August 2017

main subject

1 reference

James F Spicer

1

1 reference

22 August 2017

Sarah M Rudman

series ordinal

2

1 reference

22 August 2017

publication date

24 June 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

5

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

245-255

1 reference

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

22 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11523-010-0140-Y

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

21 January 2018

1 reference

12 December 2020

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

12 December 2020

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

1 reference

12 December 2020

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

12 December 2020

Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts

1 reference

12 December 2020

The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.

1 reference

12 December 2020

The EGF receptor family as targets for cancer therapy

1 reference

12 December 2020

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

1 reference

12 December 2020

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

12 December 2020

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

1 reference

12 December 2020

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

12 December 2020

EGF-ERBB signalling: towards the systems level

1 reference

12 December 2020

Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy

1 reference

12 December 2020

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

1 reference

12 December 2020

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

1 reference

12 December 2020

A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer

1 reference

12 December 2020

Tyrosine kinases as targets for cancer therapy

1 reference

12 December 2020

Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features

1 reference

12 December 2020

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

12 December 2020

Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors

1 reference

12 December 2020

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

12 December 2020

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

12 December 2020

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

1 reference

12 December 2020

EGFR and cancer prognosis

1 reference

12 December 2020

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib

1 reference

12 December 2020

Where next for gefitinib in patients with lung cancer?

1 reference

12 December 2020

First- and second-line therapy for advanced nonsmall cell lung cancer.

1 reference

12 December 2020

Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members

1 reference

12 December 2020

EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.

1 reference

12 December 2020

The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors

1 reference

12 December 2020

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib

1 reference

12 December 2020

EGFR exon 20 insertion mutation in Japanese lung cancer

1 reference

12 December 2020

Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib

1 reference

12 December 2020

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

12 December 2020

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

12 December 2020

Epidermal growth factor receptor mutations in lung cancer

1 reference

12 December 2020

HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy

1 reference

12 December 2020

Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).

1 reference

12 December 2020

Cetuximab in advanced non-small cell lung cancer

1 reference

12 December 2020

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

12 December 2020

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

12 December 2020

Comparing antibody and small-molecule therapies for cancer

1 reference

12 December 2020

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

12 December 2020

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

1 reference

12 December 2020

Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma

1 reference

12 December 2020

Salvage therapy in patients with advanced non-small cell lung cancer

1 reference

12 December 2020

HKI-272 in non small cell lung cancer.

1 reference

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

EGFR antagonists in cancer treatment

1 reference

12 December 2020

Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma

1 reference

12 December 2020

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

12 December 2020

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

1 reference

12 December 2020

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

12 December 2020

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

1 reference

12 December 2020

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

1 reference

12 December 2020

Detection of mutations in EGFR in circulating lung-cancer cells

1 reference

12 December 2020

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

12 December 2020

EGFR tyrosine kinase inhibitors in lung cancer: an evolving story

1 reference

12 December 2020

Why the epidermal growth factor receptor? The rationale for cancer therapy

1 reference

12 December 2020

Erlotinib in previously treated non-small-cell lung cancer

1 reference

12 December 2020

Deaths: final data for 2005.

1 reference

12 December 2020

Update on epidermal growth factor receptor mutations in non-small cell lung cancer

1 reference

12 December 2020

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

1 reference

12 December 2020

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

12 December 2020

Targeted therapies for the treatment of breast cancer in the post-trastuzumab era.

1 reference

12 December 2020

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

12 December 2020

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

1 reference

12 December 2020

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

12 December 2020

Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions

1 reference

12 December 2020

Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas

1 reference

12 December 2020

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

1 reference

12 December 2020

10.1007/S11523-010-0140-Y

Identifiers

DOI

1 reference

22 August 2017

1 reference